Laurin Rinder / Shutterstock.com
The English High Court has dismissed an application by Eli Lilly to stop Human Genome Sciences (HGS) from receiving a supplementary protection certificate (SPC) based on a marketing authorisation Lilly may receive for a new drug.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
English High Court, Eli Lilly, GSK, HGS, SPCs